AbbVie: Depressive Disorder trials

The registry lists 53 Depressive Disorder studies with AbbVie as lead sponsor. 0 are open to participants now and 40 have results posted.

Phase 1 3Phase 2 12Phase 3 30Phase 4 6No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants AloneCompletedNCT03738215Phase 3Results posted
• Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)TerminatedNCT03675776Phase 3Results posted
• Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)TerminatedNCT03668600Phase 3Results posted
• Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)TerminatedNCT03614156Phase 3Results posted
• Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive DisorderCompletedNCT03569475Phase 3Results posted
• Study of Rapastinel as Monotherapy in Patients With MDDTerminatedNCT03560518Phase 3Results posted
• A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive DisorderTerminatedNCT03352453Phase 2Results posted
• Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive DisorderCompletedNCT03002077Phase 3Results posted
• A Study to Evaluate the Effectiveness of Juvéderm® VOLIFT®™ With Lidocaine for Dynamic Radial Cheek Line Skin DepressionsCompletedNCT02980783Phase 4Results posted
• A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive DisorderCompletedNCT02951988Phase 3Results posted
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)CompletedNCT02943564Phase 3Results posted
• A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)CompletedNCT02932943Phase 3Results posted
• Study on the Efficacy, Safety, and Tolerability of Cariprazine Relative to Placebo in Participants With Bipolar I DepressionCompletedNCT02670551Phase 3Results posted
• A Study of Vilazodone in Pediatric Patients With Major Depressive DisorderCompletedNCT02436239Phase 3Results posted
• Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive DisorderCompletedNCT02431806Phase 3Results posted
• Safety and Efficacy of Vilazodone in Pediatric Patients With Major Depressive Disorder (VLZ-MD-22)CompletedNCT02372799Phase 3Results posted
• A Multicenter, Relapse Prevention Study With Levomilnacipran Extended Release (ER) in Participants With Major Depressive DisorderCompletedNCT02288325Phase 4Results posted
• Open Label Extension for GLYX13-C-202, NCT01684163TerminatedNCT02192099Phase 2Results posted
• A Prospective, Open Label Study Evaluating JUVÉDERM® VOLBELLA With Lidocaine Treatment for the Correction of Skin Depressions in the Infra-orbital AreaCompletedNCT02176421Not applicableResults posted
• OnabotulinumtoxinA as Treatment for Major Depressive Disorder in Adult FemalesCompletedNCT02116361Phase 2Results posted
• Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive DisorderCompletedNCT01878292Phase 3Results posted
• Long-term Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy in Patients With Major Depressive DisorderCompletedNCT01838876Phase 3Results posted
• Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD)CompletedNCT01715805Phase 3Results posted
• Safety, Efficacy, and Tolerability of Vilazodone in Major Depressive DisorderCompletedNCT01473394Phase 4Results posted
• Safety and Efficacy of Vilazodone in Major Depressive DisorderCompletedNCT01473381Phase 4Results posted
• Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive DisorderCompletedNCT01469377Phase 2Results posted
• Safety, Tolerability, and Efficacy of Cariprazine in Participants With Bipolar DepressionCompletedNCT01396447Phase 2Results posted
• Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive DisorderCompletedNCT01377194Phase 3Results posted
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Adults With Fatigue Associated With Major Depressive DisorderCompletedNCT01254305Phase 2Results posted
• Safety Study of Escitalopram in Children 7 to 11 Years of Age With Major Depressive DisorderCompletedNCT01198795Phase 4Results posted
• Relapse-Prevention Study With Levomilnacipran ER (F2695 SR) in Patients With Major Depressive DisorderCompletedNCT01085812Phase 3Results posted
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderCompletedNCT01034462Phase 3Results posted
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderCompletedNCT00969709Phase 3Results posted
• Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive DisorderCompletedNCT00969150Phase 3Results posted
• Safety and Efficacy of Cariprazine As Adjunctive Therapy In Major Depressive DisorderCompletedNCT00854100Phase 2Results posted
• Safety and Efficacy of RGH-188 (Cariprazine) in Bipolar DepressionCompletedNCT00852202Phase 2Results posted
• Randomized, Double-Blind, Placebo Controlled Study of Vilazodone's Efficacy, Safety, and Biomarkers of Response in Major Depressive Disorder (MDD)CompletedNCT00683592Phase 3Results posted
• Escitalopram in Adult Patients With Major Depressive DisorderCompletedNCT00668525Phase 3Results posted
• A One Year Open Label Study Assessing the Safety and Tolerability of Vilazodone in Patients With Major Depressive Disorder (MDD)CompletedNCT00644358Phase 3Results posted
• The Safety and Efficacy of Escitalopram in Pediatric Patients With Major Depressive DisorderCompletedNCT00107120Phase 3Results posted
• Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World SettingCompletedNCT05956483
• A Study of SDI-118 in Participants in Remission From DepressionWithdrawnNCT05212116Phase 1
• Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)WithdrawnNCT03855865Phase 3
• Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy VolunteersCompletedNCT02366364Phase 1
• Study of Intravenous NRX-1074 in Patients With Major Depressive DisorderCompletedNCT02067793Phase 2
• Efficacy and Safety Study of ABT-436 in Major Depressive DisorderTerminatedNCT01741142Phase 2
• Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to AntidepressantsCompletedNCT01684163Phase 2
• Safety and Pharmacodynamic Study of ABT-436 in Major Depressive DisorderCompletedNCT01380704Phase 1
• Single IV Dose of GLYX-13 in Patients With Treatment-Resistant DepressionCompletedNCT01234558Phase 2
• Safety Study of F2695 SR in Major Depressive DisorderCompletedNCT01034267Phase 3
• Fixed Dose Comparison of Escitalopram to an Active Comparator in Severely Depressed PatientsCompletedNCT00384436Phase 4
• Comparison of Escitalopram Combination in Adult Patients With Major Depressive DisorderCompletedNCT00109044Phase 3
• Study of Escitalopram in Adult Patients With Major Depressive DisorderCompletedNCT00108979Phase 3